Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Global secretome analysis identifies novel mediators of bone metastasis.

Blanco MA, LeRoy G, Khan Z, Alečković M, Zee BM, Garcia BA, Kang Y.

Cell Res. 2012 Sep;22(9):1339-55. doi: 10.1038/cr.2012.89.

2.

Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.

Jin L, Zhang Y, Li H, Yao L, Fu D, Yao X, Xu LX, Hu X, Hu G.

Cell Res. 2012 Sep;22(9):1356-73. doi: 10.1038/cr.2012.90.

3.

Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.

Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, Zielinski C, Pehamberger H, Gerner C.

J Proteome Res. 2009 May;8(5):2501-10. doi: 10.1021/pr8010827.

PMID:
19222175
4.

Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling.

Chiu KH, Chang YH, Wu YS, Lee SH, Liao PC.

J Proteome Res. 2011 Mar 4;10(3):1110-25. doi: 10.1021/pr1008724.

PMID:
21186846
5.

Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment.

Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH.

Mol Cell Proteomics. 2015 Mar;14(3):471-83. doi: 10.1074/mcp.M114.039909.

6.

Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.

de Wit M, Kant H, Piersma SR, Pham TV, Mongera S, van Berkel MP, Boven E, Pontén F, Meijer GA, Jimenez CR, Fijneman RJ.

J Proteomics. 2014 Mar 17;99:26-39. doi: 10.1016/j.jprot.2014.01.001.

PMID:
24418523
7.

Proteomic signatures of the desmoplastic invasion front reveal collagen type XII as a marker of myofibroblastic differentiation during colorectal cancer metastasis.

Karagiannis GS, Petraki C, Prassas I, Saraon P, Musrap N, Dimitromanolakis A, Diamandis EP.

Oncotarget. 2012 Mar;3(3):267-85.

8.

Secretome protein signature of human pancreatic cancer stem-like cells.

Brandi J, Dalla Pozza E, Dando I, Biondani G, Robotti E, Jenkins R, Elliott V, Park K, Marengo E, Costello E, Scarpa A, Palmieri M, Cecconi D.

J Proteomics. 2016 Mar 16;136:1-12. doi: 10.1016/j.jprot.2016.01.017.

PMID:
26850699
9.

SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Kashyap MK, Harsha HC, Renuse S, Pawar H, Sahasrabuddhe NA, Kim MS, Marimuthu A, Keerthikumar S, Muthusamy B, Kandasamy K, Subbannayya Y, Prasad TS, Mahmood R, Chaerkady R, Meltzer SJ, Kumar RV, Rustgi AK, Pandey A.

Cancer Biol Ther. 2010 Oct 15;10(8):796-810.

10.

Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome.

Marimuthu A, Chavan S, Sathe G, Sahasrabuddhe NA, Srikanth SM, Renuse S, Ahmad S, Radhakrishnan A, Barbhuiya MA, Kumar RV, Harsha HC, Sidransky D, Califano J, Pandey A, Chatterjee A.

Biochim Biophys Acta. 2013 Nov;1834(11):2308-16. doi: 10.1016/j.bbapap.2013.04.029.

PMID:
23665456
11.

New secrets behind bone metastasis.

Guo X, Wang XF.

Cell Res. 2012 Sep;22(9):1309-11. doi: 10.1038/cr.2012.99.

12.

The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.

Schaaij-Visser TB, de Wit M, Lam SW, Jiménez CR.

Biochim Biophys Acta. 2013 Nov;1834(11):2242-58. doi: 10.1016/j.bbapap.2013.01.029. Review.

PMID:
23376433
13.

Primary effusion lymphoma: secretome analysis reveals novel candidate biomarkers with potential pathogenetic significance.

Gloghini A, Volpi CC, Caccia D, Gualeni AV, Cilia AM, Carbone A, Bongarzone I.

Am J Pathol. 2014 Mar;184(3):618-30. doi: 10.1016/j.ajpath.2013.11.028.

PMID:
24521760
14.

Low-molecular-mass secretome profiling identifies C-C motif chemokine 5 as a potential plasma biomarker and therapeutic target for nasopharyngeal carcinoma.

Lin SJ, Chang KP, Hsu CW, Chi LM, Chien KY, Liang Y, Tsai MH, Lin YT, Yu JS.

J Proteomics. 2013 Dec 6;94:186-201. doi: 10.1016/j.jprot.2013.09.013.

PMID:
24080422
15.

Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112.

16.

Identification of prospective factors promoting osteotropism in breast cancer: a potential role for CITED2.

Lau WM, Weber KL, Doucet M, Chou YT, Brady K, Kowalski J, Tsai HL, Yang J, Kominsky SL.

Int J Cancer. 2010 Feb 15;126(4):876-84. doi: 10.1002/ijc.24780.

17.

A high-quality secretome of A549 cells aided the discovery of C4b-binding protein as a novel serum biomarker for non-small cell lung cancer.

Luo X, Liu Y, Wang R, Hu H, Zeng R, Chen H.

J Proteomics. 2011 Apr 1;74(4):528-38. doi: 10.1016/j.jprot.2011.01.011.

PMID:
21262398
18.

Quantitative secretome analysis reveals the interactions between epithelia and tumor cells by in vitro modulating colon cancer microenvironment.

Zeng X, Yang P, Chen B, Jin X, Liu Y, Zhao X, Liang S.

J Proteomics. 2013 Aug 26;89:51-70. doi: 10.1016/j.jprot.2013.05.032.

19.

Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis.

Gilkes DM, Bajpai S, Wong CC, Chaturvedi P, Hubbi ME, Wirtz D, Semenza GL.

Mol Cancer Res. 2013 May;11(5):456-66. doi: 10.1158/1541-7786.MCR-12-0629.

20.

Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry.

Alldridge L, Metodieva G, Greenwood C, Al-Janabi K, Thwaites L, Sauven P, Metodiev M.

J Proteome Res. 2008 Apr;7(4):1458-69. doi: 10.1021/pr7007829.

PMID:
18257521

Supplemental Content

Support Center